论文部分内容阅读
临床为了控制慢性哮喘病人的发作,血清茶碱浓度必须达到8—20μg/ml。要维持这水平,应用茶碱必须个体化,且需通过临床症状及测定的血药浓度作指导。本文旨在研究一种新型茶碱缓释剂的生物利用度;血浆与唾液浓度比率的大小和差异;血浆茶碱浓度、CAMP含量和心脏作用间的关系等。 12名受试者,每人1次静注200mg茶碱(=240mg氨荣碱)以及单次剂量280mg—羟茶碱(=350mg氨茶碱),480mg—羟茶碱(=600mg氨茶碱)和280mg缓释剂—羟茶碱。随机给药。每次试验间隔至少3天。给药后1分钟到12小时同时采取血和唾液以
Clinical In order to control the onset of chronic asthma patients, serum theophylline concentration must reach 8-20μg / ml. To maintain this level, application of theophylline must be individualized and guided by clinical symptoms and the measured plasma concentration. This article aims to study the bioavailability of a new theophylline sustained-release agent; plasma and saliva concentration ratio of the size and differences; plasma theophylline concentration, CAMP content and the relationship between heart function. Twelve subjects were injected intravenously with 200 mg of theophylline (= 240 mg of ammonia-base) and 280 mg of theophylline (= 350 mg of aminophylline), 480 mg of theophylline (= 600 mg of aminophylline ) And 280 mg of slow-release agent-hydroxytheophylline. Random administration. Each test interval of at least 3 days. 1 minute to 12 hours after administration of blood and saliva at the same time